TCRT
Alaunos Therapeutics, Inc. NASDAQ Listed Aug 24, 2005$2.08
-3.70%
vs $2.16
Mkt Cap $4.1M
52w Low $1.77
9.3% of range
52w High $5.11
50d MA $2.44
200d MA $2.90
P/E (TTM)
-1.0x
EV/EBITDA
—
P/B
1.9x
Debt/Equity
0.0x
ROE
-194.0%
P/FCF
-1.4x
RSI (14)
42.70
ATR (14)
$0.12
Beta
-1.13
50d MA
$2.44
200d MA
$2.90
Avg Volume
19.3K
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas.
8030 El Rio Street · Houston, TX 77054 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2026 | AMC | -3.69 | -0.40 | +89.1% | 2.86 | +0.3% | +3.1% | -0.7% | -2.0% | +1.7% | -0.3% | — |
| Nov 14, 2025 | AMC | -4.90 | -0.55 | +88.8% | 2.97 | +0.7% | +8.4% | +3.7% | -0.9% | +7.3% | -11.0% | — |
| Aug 14, 2025 | AMC | -5.33 | -0.63 | +88.2% | 2.40 | +0.0% | -6.2% | +3.6% | -3.9% | -7.6% | -8.7% | — |
| May 15, 2025 | AMC | -6.44 | -0.67 | +89.6% | 2.82 | +3.9% | +0.7% | -5.3% | -1.9% | -3.8% | +3.9% | — |
| Mar 31, 2025 | AMC | -4.50 | -0.46 | +89.8% | 1.47 | -2.0% | +46.9% | +29.6% | +50.7% | -30.1% | +1.7% | — |
| Nov 14, 2024 | AMC | -4.50 | -0.70 | +84.4% | 2.34 | +3.0% | -10.7% | +2.4% | -1.4% | +0.9% | +8.9% | — |
| Aug 14, 2024 | AMC | -4.50 | -0.71 | +84.2% | 2.42 | +0.0% | -2.9% | -3.0% | -4.4% | +37.2% | -13.7% | — |
| May 15, 2024 | AMC | -4.50 | -1.10 | +75.6% | 11.90 | -1.7% | +2.5% | -4.9% | -4.3% | -3.6% | +0.0% | — |
| Apr 2, 2024 | AMC | -0.45 | -0.49 | -8.9% | 17.60 | -4.0% | +3.4% | -2.2% | -3.9% | -2.9% | +4.2% | — |
| Nov 14, 2023 | AMC | -4.50 | -6.00 | -33.3% | 11.15 | -4.5% | +0.9% | -6.7% | -3.7% | +14.5% | -3.7% | — |
| Aug 14, 2023 | AMC | -6.00 | -6.00 | +0.0% | 59.04 | -49.7% | -64.7% | +12.5% | -16.1% | -5.9% | +15.8% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 15 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $59.04 | $29.70 | -49.7% | -64.7% | +12.5% | -16.1% | -5.9% | +15.8% |
| Aug 14 | Laidlaw & Co. | Downgrade | Buy → Hold | — | $59.99 | $61.50 | +2.5% | -1.6% | -64.7% | +12.5% | -16.1% | -5.9% |
| May 14 | HC Wainwright & Co. | Upgrade | Neutral → Buy | — | — | — | — | — | — | — | — | — |
| May 3 | Wells Fargo | Upgrade | Equal Weight → Overweight | — | $73.91 | $80.60 | +9.1% | +12.7% | +36.0% | -17.1% | +10.2% | -1.4% |
| Nov 8 | Raymond James | Maintains | Market Perform → Market Perform | — | $243.00 | $240.00 | -1.2% | +0.6% | -2.5% | -5.7% | +4.0% | -2.6% |
| Aug 9 | Raymond James | Downgrade | Outperform → Market Perform | — | $340.50 | $342.00 | +0.4% | +0.9% | -16.2% | -2.1% | -0.5% | -4.8% |
| May 6 | Raymond James | Maintains | Outperform → Outperform | — | $454.50 | $451.50 | -0.7% | -1.3% | +7.0% | -6.9% | +4.0% | -1.0% |
| Mar 11 | Jefferies | Downgrade | Buy → Hold | — | $720.00 | $735.00 | +2.1% | +0.4% | -8.9% | -1.3% | -1.3% | -1.9% |
| Feb 28 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | — | — | — | — | — | — | — | — |
| Mar 2 | Raymond James | Maintains | Outperform → Outperform | — | $463.50 | $468.00 | +1.0% | +1.5% | -7.5% | +9.0% | -4.7% | +8.0% |
| Nov 14 | Raymond James | Upgrade | Market Perform → Outperform | — | $405.00 | $411.00 | +1.5% | +0.0% | +14.1% | +3.9% | -4.1% | +1.0% |
| Jun 17 | JP Morgan | Downgrade | Neutral → Underweight | — | — | — | — | — | — | — | — | — |
| Aug 9 | Wells Fargo | Upgrade | Underperform → Market Perform | — | $730.50 | $727.50 | -0.4% | -0.2% | +5.8% | +1.4% | +4.8% | +7.3% |
| Jun 21 | BMO Capital | Downgrade | Outperform → Market Perform | — | — | — | — | — | — | — | — | — |
| Mar 9 | Mizuho | Downgrade | Buy → Neutral | — | $2007.00 | $2016.00 | +0.4% | +4.0% | -5.3% | -0.3% | -1.3% | +2.7% |
| Jan 13 | BMO Capital | Upgrade | Underperform → Outperform | — | $889.50 | $906.00 | +1.9% | -3.2% | +54.5% | -10.1% | +1.8% | -6.0% |
| Mar 3 | Piper Sandler | Upgrade | Underweight → Neutral | — | $639.00 | $628.50 | -1.6% | -1.2% | +5.7% | -0.2% | -2.7% | -1.9% |
| Mar 26 | Brinson Patrick | Downgrade | Outperform → Market Perform | — | $769.50 | $286.50 | -62.8% | -64.5% | -5.5% | +6.4% | -3.8% | -3.4% |
| Mar 25 | BMO Capital | Downgrade | Market Perform → Underperform | — | $727.50 | $729.00 | +0.2% | +5.8% | -64.5% | -5.5% | +6.4% | -3.8% |
| Mar 25 | JP Morgan | Downgrade | Overweight → Neutral | — | $727.50 | $729.00 | +0.2% | +5.8% | -64.5% | -5.5% | +6.4% | -3.8% |
| Mar 25 | Piper Sandler | Downgrade | Neutral → Underweight | — | $727.50 | $729.00 | +0.2% | +5.8% | -64.5% | -5.5% | +6.4% | -3.8% |
| Mar 25 | Jefferies | Maintains | Hold → Hold | — | $727.50 | $729.00 | +0.2% | +5.8% | -64.5% | -5.5% | +6.4% | -3.8% |
| Dec 11 | Jefferies | Downgrade | Buy → Hold | — | $613.50 | $621.00 | +1.2% | +8.6% | -6.1% | -1.7% | -0.5% | -0.2% |
| Mar 1 | Jefferies | Maintains | Buy → Buy | — | $736.50 | $736.50 | +0.0% | -6.1% | +0.9% | +0.2% | +0.4% | +1.9% |
No insider trades available.
8-K · 8.01
!! High
Alaunos Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Alaunos Therapeutics' ALN1003 demonstrated reduced liver weight in preclinical study DIO Study 1, suggesting potential metabolic benefits independent of body composition changes, supporting further development of this therapeutic candidate.
Jun 29
8-K · 8.01
!! High
Alaunos Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Alaunos Therapeutics reported preclinical mouse study results for ALN1003 obesity treatment, though findings remain preliminary and unproven in humans, limiting investment relevance until clinical trials commence.
May 26
8-K · 8.01
!! High
Alaunos Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Alaunos Therapeutics' ALN1003 candidate showed preclinical promise but remains unproven in humans, requiring investors to exercise caution regarding its clinical development timeline and ultimate commercial viability.
May 18
8-K
Unknown — 8-K Filing
TCRT risks delisting if it fails to regain Nasdaq compliance within 180 days, threatening liquidity and institutional investor access to the stock.
Apr 15
8-K · 8.01
!! High
Alaunos Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Alaunos Therapeutics (TCRT) made a material announcement, though the specific details require reviewing the attached press release exhibit to assess investment implications.
Mar 2
Valuation
Market Cap
$4.1M
Enterprise Value
$2.7M
P/E (TTM)
-0.96x
Forward P/E
—
PEG Ratio
0.06x
P/B
1.88x
P/S
1350.86x
P/FCF
-1.37x
EV/EBITDA
—
Shares Out
1.9M
Financials (TTM)
Revenue
$3K
Net Income
-$4.1M
EBITDA
-$4.1M
Free Cash Flow
-$3.0M
Op Cash Flow
-$2.9M
EPS Basic
$-2.20
EPS Diluted
$-2.17
EPS Forward
$-21.00
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$3.0M
Total Liab.
$813K
Total Equity
$2.2M
Cash
$1.4M
LT Debt
$0
Book Value/Sh
$1.10
Debt/Equity
0.00x
Current Ratio
2.45
Quick Ratio
2.45
Returns & Growth
ROE
-194.0%
ROA
-140.8%
ROIC
-196.2%
Rev Growth YoY
-50.0%
EPS Growth YoY
+24.7%
Price Returns
2W
-6.3%
1M
-20.6%
3M
-27.5%
6M
-36.6%
12M
-58.4%
Technicals
52W High
$5.11
52W Low
$1.77
50d MA
$2.44
200d MA
$2.90
RSI (14)
42.70
ATR (14)
$0.12
Beta
-1.13
Avg Volume
19K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 27, 2026 4:12am
· Source: financialmodelingprep.com